Insulia Receives FDA Clearance, CE Mark to Integrate Basaglar, Tresiba

Voluntis announced that Insulia, its digital companion for people with Type 2 diabetes, has received FDA clearance and the CE mark to integrate Basaglar and Tresiba. This now makes Insulia available for people using any brand of basal insulin including Lantus, Levemir, Toujeo, Tresiba and Basaglar. Voluntis will continue to work to make Insulia available to those using other insulin therapies, including NPH insulin and GLP-1/basal insulin combinations, aiming for release in 2018.

"It's complicated enough worrying about how to titrate your insulin, without having to worry about whether your brand of insulin is compatible with automatic titration tools such as Insulia," said Pierre Leurent, CEO of Voluntis. "We are very excited to make Insulia available to all those with type 2 diabetes, regardless of the basal insulin brand they're using."

Insulia is a prescription-only digital companion for people with type 2 diabetes and their care teams that helps people get to the right dose, every day. Insulia combines a patient mobile app and health care practitioner (HCP) web portal. The mobile app provides real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose values. The HCP web portal allows HCPs to configure personalized treatment plans and prescribe the app then follow their entire patient population remotely. Once a healthcare practitioner has issued the prescription, Insulia is available for download on the App Store and Google Play.